Market Research Logo

Asia Pacific Gerd Drugs And Devices Market Forecast 2019-2027

Asia Pacific Gerd Drugs And Devices Market Forecast 2019-2027

KEY FINDINGS

The APAC region market for GERD drugs and devices account growth of 1.52% CAGR through the forecasted years of 2019-2027. This region includes Japan, China, India, South Korea, Australia and the Rest of Asia.

MARKET INSIGHTS

The largest revenue contributor to the APAC market for GERD drugs and devices are Japan, China and India because of driving factors like availability of fewer approved drugs to treat GERD and increasing awareness about GERD among the patients that are pushing the growth of this market.

COMPETITIVE INSIGHTS

Some of the companies that provides additional revenue of the global GERG drugs and devices market are Abbott Laboratories, AstraZeneca, Ausch Health (Formerly Valeant Pharmaceuticals International, Inc.), Boston Scientific Corporation, Cempra Inc. (Merged with Melinta), Daewoong Co. Ltd., Eisai Inc., Glaxosmithkline, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co. Inc., Novartis, Pfizer, Inc., RaQualia Pharma Inc. and Takeda Pharmaceuticals Company Limited.


1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top Down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
3.2.1. Antacids Drug Class Holds The Largest Market Share
3.2.2. Bravo System Devices Are Widely Used
4. Market Dynamics
4.1. Market Scope & Definition
4.2. Market Drivers
4.2.1. Growing Trend Of Self-medication
4.2.2. Increasing Awareness About Gerd
4.2.3. Increasing Occurrence Of Gerd Disorders
4.2.4. Changes In Lifestyle
4.3. Market Restraints
4.3.1. Patent Expiry
4.3.2. Adverse Effect Of Proton Pump Inhibitors And Other Drugs
4.3.3. Proton Pump Inhibitor Resistance
4.4. Market Opportunities
4.4.1. Increased Practice Of Generics And Otc Drugs
4.4.2. Cost-effective Otc Drugs
4.4.3. Overuse Of Medication And Dietary Supplements
4.5. Market Challenges
4.5.1. Use Of Complementary And Alternative Treatments
4.5.2. Probability Of Buying Counterfeit Drugs
4.6. Market By Drugs Dosage Form
4.7. Market By Route Of Administration Of Drugs
5. Market By Drugs And Devices
5.1. Drug Class
5.1.1. Antacids
5.1.2. H2 Receptor Blockers
5.1.3. Proton Pump Inhibitors (Ppi)
5.1.4. Pro-kinetic Agents
5.2. Devices
5.2.1. Digitrapper
5.2.2. Bravo System
5.2.3. Stretta
5.2.4. Linx Reflux Management System
5.2.5. Muse (Medigus Ultrasonic Surgical Endostapler) System
5.2.6. Other Devices
6. Key Analytics
6.1. Porter’s Five Force Model
6.1.1. Threat Of New Entrants
6.1.2. Threat Of Substitute
6.1.3. Bargaining Power Of Suppliers
6.1.4. Bargaining Power Of Buyers
6.1.5. Threat Of Competitive Rivalry
6.2. Pipeline Drugs
6.3. Regulatory Framework
6.4. Patent Analysis
6.5. Opportunity Matrix
7. Geographical Analysis
7.1. Asia Pacific
7.1.1. Japan
7.1.2. China
7.1.3. India
7.1.4. Australia
7.1.5. South Korea
7.1.6. Rest Of Asia Pacific
8. Competitive Landscape
8.1. Market Share Analysis
8.2. Company Profiles
8.2.1. Abbott Laboratories.
8.2.1.1. Company Overview
8.2.1.2. Product Portfolio
8.2.1.3. Scot Analysis
8.2.1.4. Strategic Initiatives
8.2.2. Astrazeneca
8.2.2.1. Company Overview
8.2.2.2. Product Portfolio
8.2.2.3. Scot Analysis
8.2.2.4. Strategic Initiatives
8.2.3. Bausch Health (Formerly Valeant Pharmaceuticals International, Inc.)
8.2.3.1. Company Overview
8.2.3.2. Product Portfolio
8.2.3.3. Scot Analysis
8.2.3.4. Strategic Initiatives
8.2.4. Boston Scientific Corporation
8.2.4.1. Company Overview
8.2.4.2. Product Portfolio
8.2.4.3. Scot Analysis
8.2.4.4. Strategic Initiatives
8.2.5. Cempra Inc. (Merged With Melinta)
8.2.5.1. Company Overview
8.2.5.2. Product Portfolio
8.2.5.3. Scot Analysis
8.2.5.4. Strategic Initiatives
8.2.6. Daewoong Co. Ltd.
8.2.6.1. Company Profiles
8.2.6.2. Product Portfolio
8.2.6.3. Strategic Initiatives
8.2.7. Eisai Inc
8.2.7.1. Company Overview
8.2.7.2. Product Portfolio
8.2.7.3. Scot Analysis
8.2.7.4. Strategic Initiatives
8.2.8. Glaxosmithkline
8.2.8.1. Company Overview
8.2.8.2. Product Portfolio
8.2.8.3. Scot Analysis
8.2.8.4. Strategic Initiatives
8.2.9. Ironwood Pharmaceuticals, Inc.
8.2.9.1. Company Overview
8.2.9.2. Product Portfolio
8.2.9.3. Scot Analysis
8.2.9.4. Strategic Initiatives
8.2.10. Johnson & Johnson
8.2.10.1. Company Overview
8.2.10.2. Product Portfolio
8.2.10.3. Scot Analysis
8.2.10.4. Strategic Initiatives
8.2.11. Merck & Co., Inc.
8.2.11.1. Company Profiles
8.2.11.2. Product Portfolio
8.2.11.3. Scot Analysis
8.2.11.4. Strategic Initiatives
8.2.12. Novartis
8.2.12.1. Company Overview
8.2.12.2. Product Portfolio
8.2.12.3. Scot Analysis
8.2.12.4. Strategic Initiatives
8.2.13. Pfizer, Inc.
8.2.13.1. Company Profiles
8.2.13.2. Product Portfolio
8.2.13.3. Scot Analysis
8.2.13.4. Strategic Initiatives
8.2.14. Raqual Ia Pharma Inc.
8.2.14.1. Company Overview
8.2.14.2. Product Portfolio
8.2.14.3. Strategic Initiatives
8.2.15. Takeda Pharmaceuticals Company Limited
8.2.15.1. Company Overview
8.2.15.2. Product Portfolio
8.2.15.3. Scot Analysis
8.2.15.4. Strategic Initiatives
List Of Tables
Table 1 Asia Pacific Gerd Drugs And Devices Market 2019-2027 ($ Million)
Table 2 Asia Pacific Gerd Drugs And Devices Market By Drugs And Devices 2019-2027 ($ Million)
Table 3 Asia Pacific Drug Class Market By Types 2019-2027 ($ Million)
Table 4 Asia Pacific Drug Class Market 2019-2027 ($ Million)
Table 5 Asia Pacific Antacids Market 2019-2027 ($ Million)
Table 6 Asia Pacific H2 Receptor Blockers Market 2019-2027 ($ Million)
Table 7 Asia Pacific H2 Receptor Blockers Market By Types 2019-2027 ($ Million)
Table 8 Asia Pacific Proton Pump Inhibitors (Ppi) Market 2019-2027 ($ Million)
Table 9 Asia Pacific Proton Pump Inhibitors (Ppi) Market By Types 2019-2027 ($ Million)
Table 10 Asia Pacific Pro-kinetic Agents Market 2019-2027 ($ Million)
Table 11 Asia Pacific Devices Market By Types 2019-2027 ($ Million)
Table 12 Asia Pacific Devices Market 2019-2027 ($ Million)
Table 13 Asia Pacific Digitrapper Market 2019-2027 ($ Million)
Table 14 Asia Pacific Bravo System Market 2019-2027 ($ Million)
Table 15 Asia Pacific Stretta (Mederitherapeutics) Market 2019-2027 ($ Million)
Table 16 Asia Pacific Linx® Reflux Management System (Torax Medical) Market 2019-2027 ($ Million)
Table 17 Asia Pacific Muse™ (Medigus Ultrasonic Surgical Endostapler) System Market 2019-2027 ($ Million)
Table 18 Asia Pacific Other Devices Market 2019-2027 ($ Million)
Table 19 Asia Pacific Gerd Drugs And Devices Market 2019-2027 ($ Million)
Table 20 Asia Pacific Gerd Drugs And Devices Market By Country 2019-2027 ($ Million)
List Of Figures
Figure 1 Asia Pacific Gerd Drugs And Devices Market By Geography 2019-2027 ($ Million)
Figure 2 Asia Pacific Gerd Drugs And Devices Market Share By Drugs And Devices 2017 & 2027 (%)
Figure 3 Porter’s Five Force Model
Figure 4 Asia Pacific Gerd Drugs And Devices Market Regional Outlook 2018 & 2027 (%)
Figure 5 Japan Gerd Drugs And Devices Market 2019-2027 ($ Million)
Figure 6 China Gerd Drugs And Devices Market 2019-2027 ($ Million)
Figure 7 India Gerd Drugs And Devices Market 2019-2027 ($ Million)
Figure 8 Australia Gerd Drugs And Devices Market 2019-2027 ($ Million)
Figure 9 South Korea Gerd Drugs And Devices Market 2019-2027 ($ Million)
Figure 10 Rest Of Asia Pacific Gerd Drugs And Devices Market 2019-2027 ($ Million)
Figure 11 Gerd Ppis Drugs Provider Company Market Share 2017 (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report